WHO WON THE DAY? Bernard Keane, Crikey politics editor: Economic growth numbers handed the government an easy win — although the ghost of superannuation continues to extend its icy hand at the Liberals. When will they exorcise this unholy spectre from beyond the tax-effective estate planning-friendly ostentatious family vault at Waverley cemetery? But given NSW and Queensland were […]
Could the TPP force Australia to adopt an American-style model of private health? Dr Matthew Rimmer, Professor of intellectual property and innovation law at QUT, explains.
The recommendation to list "abortion pill" mifepristone on the PBS is a victory for women's rights, but obstacles remain, including the time period it can be used and who can prescribe it. Gynaecological experts Caroline de Costa and Michael Carrette explain.
The long campaign to provide Australian women with access to medical abortion will near an end today -- but what will an Abbott government do on RU486?
The fanfare around Health Minister Nicola Roxon’s announcement that 13 new medicines would go on the PBS is a reminder of the power and influence involved in the selection and reimbursement of prescribed medicines, writes Glenn Salkeld.
Shakira Hussein was relieved to see her MS drug make the PBS approved list, but she's not going to break open the metaphorical non-alcoholic champagne until the government reverses its decision to subject drugs recommended for subsidy to cabinet decision-making.
Academic -- and MS sufferer -- Shakira Hussein writes about the difficulty of expensive but critical drugs she relies on being left off the PBS approved drug list.
Sony has been cracked yet again, confirming its shocking state of cyber-security. How many other firms are in the same (lulz)boat?
The cost of the PBS must be sustainable but there is a difference between saving money and ensuring cost-effectiveness. The treatment of macular degeneration provides a compelling example, writes Ken Harvey, Richard Day, Willie Campbell, and Wendy Lipworth.